Overview

Role of Anti-IgE in Severe Childhood Eczema

Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of anti-IgE (Omalizumab/Xolair) in children with severe eczema.
Phase:
Phase 4
Details
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborators:
King's College London
National Institute for Health Research, United Kingdom
Treatments:
Omalizumab